Alnylam slips after trimming 2026 product sales forecast
ALNY•Quarterly results
The company posted Q2 sales of $1.29 billion, below analysts' estimates of $1.32 billion according to LSEG data. It reported Q2 adjusted EPS of $1.84, compared with estimates of $1.55.
Stock performance
As of the last close, the stock was down 27.9% year to date.
Shares fall after forecast cut
Shares of drugmaker Alnylam Pharmaceuticals ALNY.O fell 21.5% to $225.00 premarket after the company trimmed its 2026 total net product revenue forecast to between $4.7 billion and $5.1 billion, from a prior view of $4.9 billion to $5.3 billion.
